SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 243
NA - Nord America 184
EU - Europa 141
SA - Sud America 1
Totale 569
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 183
CN - Cina 92
SG - Singapore 90
IT - Italia 70
GB - Regno Unito 42
ID - Indonesia 35
HK - Hong Kong 12
FI - Finlandia 8
KR - Corea 8
DE - Germania 5
NL - Olanda 3
RU - Federazione Russa 3
TR - Turchia 3
CH - Svizzera 2
JP - Giappone 2
PL - Polonia 2
UA - Ucraina 2
BR - Brasile 1
CA - Canada 1
CZ - Repubblica Ceca 1
EE - Estonia 1
FR - Francia 1
LB - Libano 1
MK - Macedonia 1
Totale 569
Salva come PNG Salva come JPEG
Città #
Singapore 47
Chandler 39
Jakarta 35
Ferrara di Monte Baldo 18
London 16
Bologna 12
Hong Kong 10
Los Angeles 8
Hounslow 6
Yongsan-gu 6
Ferrara 5
Princeton 5
Ashburn 4
Chicago 4
Chiswick 4
Florence 4
Helsinki 4
Lappeenranta 4
Potomac 3
Southwark 3
Asciano 2
Beijing 2
Frankfurt Am Main 2
Frankfurt am Main 2
Gdansk 2
Islington 2
Livorno 2
Monza 2
Nakanishi 2
Naples 2
Parma 2
Rotterdam 2
Saha-gu 2
Sciacca 2
Shanghai 2
Sivas 2
Wandsworth 2
Americana 1
Amsterdam 1
Arezzo 1
Bremen 1
Brescia 1
Cologno Monzese 1
Forest City 1
Kilburn 1
Milan 1
New Bedfont 1
New Jersey 1
Ottawa 1
Paris 1
Pasadena 1
Plaistow 1
Prilep 1
Rockville 1
Rome 1
Saint Petersburg 1
Seravezza 1
Tallinn 1
Trenton 1
Verona 1
Washington 1
Xuzhou 1
Totale 296
Salva come PNG Salva come JPEG
Nome #
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 29
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 21
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 21
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 20
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 18
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 17
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 15
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 15
COVID and Lung Cancer 15
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 13
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 12
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 12
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 11
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 11
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 11
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 10
Recombinant transmembrane CD59 (CD59-TM) confers complement resistence to GPI-anchored protein detective melanoma cells. 10
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 10
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 10
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 10
The emerging role of cancer nanotechnology in the panorama of sarcoma 10
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 9
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 9
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 9
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 9
Challenges in lung cancer therapy during the COVID-19 pandemic 9
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 9
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 9
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 8
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 8
Biomarkers for immune checkpoint inhibitors--authors' reply 8
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 8
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 8
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 8
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 7
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 7
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 7
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 7
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 7
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 7
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 7
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 6
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 6
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 6
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 6
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 6
The future of mesothelioma treatment: time to shift gear 6
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 5
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 5
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 5
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 5
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 5
Epigenetic immunomodulation of hematopoietic malignancies 5
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 5
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 5
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 5
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 5
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 5
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 5
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 5
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 4
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 4
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 4
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 4
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 4
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 4
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 4
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 4
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 3
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 3
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 3
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 3
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 3
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 3
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 3
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 3
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 3
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 3
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 3
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 3
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 3
Immune checkpoint blockade in malignant mesothelioma 2
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 2
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 2
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 2
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 2
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 1
Totale 644
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.315
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 97
Totale 23.412
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/2025182 78 104 0 0 0 0 0 0 0 0 0 0
Totale 644